Pharmaceuticals

Gene Therapy Bioassays Market Future Outlook: Strong Growth Expected Toward $2.62 Billion by 2030

March 4, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the gene therapy bioassays market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Gene Therapy Bioassays Market by the end of 2030?

The gene therapy bioassays market has seen substantial growth recently. This market is expected to expand from $1.21 billion in 2025 to $1.41 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 16.5%. The historical growth of this market is linked to an increase in gene therapy research programs, the expansion of viral vector manufacturing, heightened clinical trial activity, the widespread adoption of standardized bioassay protocols, and intensifying regulatory oversight on gene therapy products.

The gene therapy bioassays market is anticipated to experience substantial expansion in the coming years, with its size projected to reach $2.62 billion by 2030, achieving a compound annual growth rate (CAGR) of 16.7%. This growth during the forecast period is primarily driven by the increasing commercialization of gene therapies, a rising demand for high-throughput bioassay solutions, the expansion of personalized genetic medicine, growing investments in advanced cell and gene therapy pipelines, and an increasing focus on assay automation and reproducibility. Key trends anticipated in this period include the increased adoption of cell-based potency assays, a rising demand for viral vector characterization tests, the growing use of automated bioassay platforms, the expansion of regulatory-compliant assay validation, and an enhanced focus on functional gene expression analysis.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33119&type=smp

What Drivers Are Shaping Future Opportunities In The Gene Therapy Bioassays Market?

The growing number of gene therapy clinical trials is anticipated to stimulate growth in the gene therapy bioassays market. These trials are conducted to assess the safety, effectiveness, and biological activity of gene-based treatments in human subjects. The proliferation of such trials is propelled by intensified research and development endeavors and increasing investment from biopharmaceutical firms dedicated to addressing unmet medical needs through innovative genetic therapies. Gene therapy bioassays are vital for clinical development, offering critical analytical evaluations to determine biological activity, potency, safety, and the mechanism of action at each phase, with regulatory mandates becoming more rigorous as programs advance through clinical stages. For instance, in January 2026, according to the Bioindustry Association (BIA), a UK-based national trade association, the UK recorded 193 ongoing advanced therapy clinical trials, over 80% of which were concentrated on gene therapies. Consequently, the surge in gene therapy clinical trials is a primary factor driving the expansion of the gene therapy bioassays market.

Which Segments Are Gaining Traction In The Gene Therapy Bioassays Market?

The gene therapy bioassays market covered in this report is segmented –

1) By Product Type: Cell-Based Assays; Viral Vector-Based Assays; Non-Viral Vector-Based Assays; Other Product Types

2) By Service Type: Assay Development Services; Assay Validation Services; Quality Control Testing Services; Regulatory Support Services; Data Analysis And Reporting Services; Custom Bioassay Design Services

3) By Application: Research And Development; Clinical Testing; Quality Control; Other Applications

4) By End User: Biotechnology Companies; Pharmaceutical Companies; Contract Research Organizations; Academic And Research Institutes; Regulatory Laboratories

Subsegments:

1) By Cell-Based Assays: Reporter Gene Expression Assays; Cell Viability And Cytotoxicity Assays; Transduction Efficiency Assays; Functional Potency Cell Assays; Cellular Uptake And Localization Assays

2) By Viral Vector-Based Assays: Adeno Associated Virus Vector Assays; Lentiviral Vector Characterization Assays; Retroviral Vector Titer Assays; Vector Genome Integrity Assays; Infectivity And Transduction Assays

3) By Non-Viral Vector-Based Assays: Plasmid Deoxyribonucleic Acid Delivery Assays; Lipid Nanoparticle Transfection Assays; Polymeric Carrier Efficiency Assays; Physical Gene Delivery Evaluation Assays; Non Viral Vector Stability Assays

4) By Other Product Types: Immunogenicity Assessment Assays; Biodistribution And Persistence Assays; Safety And Toxicity Bioassays; Analytical Method Development Assays; Custom Gene Therapy Bioassays

Which Trends Are Expected To Influence The Gene Therapy Bioassays Market In The Upcoming Years?

Major companies within the gene therapy bioassays market are increasingly focusing on incorporating artificial intelligence and machine learning into bioassay analysis, particularly through AI-enabled digital PCR data interpretation. This integration aims to bolster accuracy, minimize experimental variability, accelerate result turnaround, and optimize the evaluation of therapeutic efficacy and safety during gene therapy development. AI-enabled dPCR data interpretation employs sophisticated algorithms to automate result analysis, differentiate genuine signals from background noise, and accurately quantify viral genomes or vector copy number with minimal human involvement. For example, in April 2025, QIAGEN N.V., a Germany-based molecular diagnostics company, launched an expansion of its QIAcuity lentivirus solutions, which included the QIAcuity RCL Quant Kit and CGT dPCR assays. These solutions feature absolute quantification powered by algorithms, support both multiplex and singleplex assay compatibility for vector genome and vector copy number analysis, and offer software-assisted data analysis workflows designed to aid regulatory-compliant decision-making in gene therapy bioassay applications.

Who Are The Top-Performing Companies In The Gene Therapy Bioassays Market In Recent Years?

Major companies operating in the gene therapy bioassays market are Boehringer Ingelheim BioXcellence, AGC Biologics, ICON plc, Lonza Group AG, SGS SA, Eurofins Scientific SE, WuXi AppTec, Charles River Laboratories International Inc., Catalent Inc, Recipharm AB, KBI Biopharma, Syngene International Limited, QPS Holdings LLC, BioAgilytix Labs (operationally independent CRO), Oxford Biomedica plc, Viralgen Vector S.L., ProtaGene Inc., Center for Breakthrough Medicines, RoslinCT, Immunologix Labs, Genezen Laboratories

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/gene-therapy-bioassays-market-report

Which Region Currently Holds The Largest Share Of The Gene Therapy Bioassays Market?

North America was the largest region in the gene therapy bioassays market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy bioassays market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Gene Therapy Bioassays Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33119&type=smp

Browse Through More Reports Similar to the Global Gene Therapy Bioassays Market 2026, By The Business Research Company

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Cell And Gene Therapy Clinical Trial Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

Cell And Gene Therapy Supply Chain Or Logistics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795